Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 8/2016

01-08-2016 | Review Article

Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases

Authors: D. Marquez-Medina, S. Popat

Published in: Clinical and Translational Oncology | Issue 8/2016

Login to get access

Abstract

Malignant pleural effusion (MPE) represents 15–35 % of pleural effusions and markedly worsens the prognosis and quality of life of patients with cancer. Malignant mesothelioma (MM) and lung adenocarcinoma are the most frequent primary and secondary causes, respectively, of MPE. Effective treatments for cancer-related MPE are warranted in order to improve symptoms, reduce the number of invasive pleural procedures, and prolong patient life. Since angiogenesis plays a key role in MPE development, the potential role of bevacizumab and other anti-angiogenic therapies have been explored in this review. No relevant phase III trials have specifically analysed the benefit from adding bevacizumab to platinum-based chemotherapy in lung cancer-related MPE. However, small retrospective series reported 71.4–93.3 % MPE control rate, a reduction in invasive procedures, and a safe profile with this combination. Being approved for the first-line treatment of non-squamous advanced NSCLC, the addition of bevacizumab should be considered for patients presenting with MPE. In addition, further studies in this are recommended. In MM, the addition of bevacizumab to platinum-based chemotherapy did not meet primary endpoints in two phase II trials. However, the beneficial results on OS reported in comparison with historical cohorts and the statistically significant benefit on PFS and OS observed in the phase III MAPS trial foretell an eventual role for the combination of platinum/pemetrexed/bevacizumab as front-line systemic therapy for pleural MM. To date, no other anti-angiogenic drug has showed significant benefit in the treatment of patients with either MPE or MM. However, new promising drugs such as ramucirumab or recombinant human endostar warrant further investigation.
Literature
1.
2.
3.
Zamboni MM, da Silva CT Jr, Baretta R, Cunha ET, Cardoso GP. Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm Med. 2015;15:29.CrossRefPubMedPubMedCentral
4.
Bradshaw M, Mansfield A, Peikert T. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep. 2013;15:207–16.CrossRefPubMedPubMedCentral
5.
Fiorelli A, Vicidomini G, Di Domenico M, Napolitano F, Messina G, Morgillo F, et al. Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. Interact Cardiovasc Thorac Surg. 2011;12:420–4.CrossRefPubMed
6.
Sack U, Hoffmann M, Zhao XJ, Chan KS, Hui DSC, Gosse H, et al. Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J. 2005;25:600–4.CrossRefPubMed
7.
8.
Duysinx BC, Corhay JL, Hubin L, Nguyen D, Henket M, Louis R. Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions. Respir Med. 2008;102:1708–14.CrossRefPubMed
9.
Gkiozos I, Tsagouli S, Charpidou A, Grapsa D, Kainis E, Gratziou C, et al. Levels of vascular endothelial growth factor in serum and pleural fluid are independent predictors of survival in advanced non-small cell lung cancer: results of a prospective study. Anticancer Res. 2015;35:1129–37.PubMed
10.
Zhang Y, Yu LK, Lu GJ, Xia N, Xie HY, Hu W, et al. Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer. Asian Pac J Cancer Prev. 2014;15:8435–40.CrossRefPubMed
11.
Qian Q, Zhan P, Sun WK, Zhang Y, Song Y, Yu LK. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control. Neoplasma. 2012;59:433–9.CrossRefPubMed
12.
Zhang Y, Yu LK, Xia N. Evaluation of serum and pleural levels of endostatin and vascular epithelial growth factor in lung cancer patients with pleural effusion. Asian Pac J Trop Med. 2012;5:239–42.CrossRefPubMed
13.
Cheng D, Kong H, Li Y. Prognostic values of VEGF and IL-8 in malignant pleural effusion in patients with lung cancer. Biomarkers. 2013;18:386–90.CrossRefPubMed
14.
Choi JH, Kim HC, Lim HY, Nam DK, Kim HS, Yi JW, et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer. 2001;33:171–9.CrossRefPubMed
15.
Pichelmayer O, Zielinski C, Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med. 2005;353:740–1.CrossRefPubMed
16.
Nasreen N, Mohammed KA, Lai Y, Antony VB. Receptor EphA2 activation with ephrin A1 suppresses growth of malignant mesothelioma (MM). Cancer Lett. 2007;258:215–22.CrossRefPubMed
17.
Hamed EA, El-Noweihi AM, Mohamed AZ, Mahmoud A. Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions. Respirology. 2004;9:81–6.CrossRefPubMed
18.
Hirayama N, Tabata C, Tabata R, Maeda R, Yasumitsu A, Yamada S, et al. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir Med. 2011;105:e137–42.CrossRef
19.
Chen D, Li X, Zhao H, Fu Y, Yao F, Hu J, et al. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion. Indian J Cancer. 2014;51:S82–5.CrossRef
20.
Lieser EA, Croghan GA, Nevala WK, Bradshaw MJ, Markovic SN, Mansfield AS. Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions. Lung Cancer. 2013;82:63–8.CrossRefPubMed
21.
Maa HC, Chao TT, Wang CY, Pei D, Liang YJ, Chen YL. VEGF-D as a marker in the aid of malignant metastatic pleural effusion diagnosis. Appl Immunohistochem Mol Morphol. 2015;23:209–14.CrossRefPubMed
22.
Ribeiro SC, Vargas FS, Antonangelo L, Marchi E, Genofre EH, Acencio MM, et al. Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion. Respirology. 2009;14:1188–93.CrossRefPubMed
23.
Shen YC, Liu MQ, Wan C, Chen L, Wang T, Wen FQ. Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion: a meta-analysis. Exp Ther Med. 2012;3:1072–6.PubMedPubMedCentral
24.
Hooper CE, Elvers KT, Welsh GI, Millar AB, Maskell NA. VEGF and sVEGFR-1 in malignant pleural effusions: association with survival and pleurodesis outcomes. Lung Cancer. 2012;77:443–9.CrossRefPubMed
25.
Demirag F, Unsal E, Yilmaz A, Caglar A. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest. 2005;128:3382–7.CrossRefPubMed
26.
Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients (pts) with malignant mesothelioma. J Clin Oncol. 2007;25:S391.
27.
Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res. 2000;6:957–65.PubMed
28.
Frederick B, Gustafson D, Bianco C, Ciardello F, Dimery I, Raben D. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys. 2006;64:33–7.CrossRefPubMed
29.
Matsumori Y, Yano S, Goto H, Nakataki E, Wedge SR, Ryan AJ, et al. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res. 2006;16:15–26.PubMed
30.
Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jürgensmeier JM, et al. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:1534–43.CrossRefPubMedPubMedCentral
31.
Bae SH, Hwang JY, Kim WJ, Yoon HH, Kim JM, Nam YH, et al. A case of cardiac amyloidosis with diuretic-refractory pleural effusions treated with bevacizumab. Korean Circ J. 2010;40:671–6.CrossRefPubMedPubMedCentral
32.
Kitamura K, Kubota K, Ando M, Takahashi S, Nishijima N, Sugano T, et al. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. Cancer Chemother Pharmacol. 2013;71:457–61.CrossRefPubMed
33.
Masago K, Fujimoto D, Fujita S, Hata A, Kaji R, Ohtsuka K, et al. Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer. Mol Clin Oncol. 2015;3:415–9.PubMed
34.
Fujii M, Iwakami SI, Ihara H, Hara M, Iwakami N, Ishiwata T, et al. Efficacy and safety of chemotherapy containing bevacizumab in patients with non-small cell lung cancer with malignant pleural effusion. Respirology. 2013;18:87.
35.
Tamiya M, Tamiya A, Yamadori T, Nakao K, Asami K, Yasue T, et al. Phase2 study of bevacizumab with carboplatin–paclitaxel for non-small cell lung cancer with malignant pleural effusion. Med Oncol. 2013;30:676.CrossRefPubMed
36.
Massarelli E, Onn A, Marom EM, Alden CM, Liu DD, Tran HT, et al. Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion. Clin Lung Cancer. 2014;15:379–86.CrossRefPubMedPubMedCentral
37.
Mulder SF, Boers-Sonderen MJ, van der Heijden HF, Vissers KC, Punt CJ, van Herpen CM. A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion. Target Oncol. 2014;9:331–8.CrossRefPubMed
38.
Liu M, Shen Y, Ruan M, Li M, Chen L. Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma. Thyroid. 2014;24:1179–83.CrossRefPubMed
39.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983–8.CrossRefPubMedPubMedCentral
40.
Hama M, Komatsu Y, Hachiya T. A case of lung cancer showing marked reduction of pleural effusion by bevacizumab in combination with carboplatin and paclitaxel. Gan To Kagaku Ryoho. 2011;38:1877–9.PubMed
41.
Du N, Li X, Li F, Zhao H, Fan Z, Ma J, et al. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncol Rep. 2013;29:2332–40.PubMed
42.
Santoro A, O’Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008;3:756–63.CrossRefPubMed
43.
Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer. 2008;60:259–63.CrossRefPubMed
44.
Li Q, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y, et al. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res. 2007;13:5918–25.CrossRefPubMed
45.
Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008;113:808–14.CrossRefPubMed
46.
Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer. 2013;109:552–8.CrossRefPubMedPubMedCentral
47.
Dowell J, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, et al. A multicenter phase II study of pemetrexed, cisplatin and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012;77:567–71.CrossRefPubMed
48.
Zalcman G, Mazieres J, Scherpereel A, Margery J, Moro-Sibilot D, Parienti JJ, et al. IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II–III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. J Clin Oncol. 2012;30:STPS7112.
49.
Zalcman G, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab 15 mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial. J Clin Oncol. 2015;33:S7500.
50.
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227–34.CrossRefPubMed
51.
Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31:3004–11.CrossRefPubMed
52.
Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:4349–57.CrossRefPubMedPubMedCentral
53.
Sartori S, Tassinari D, Ceccotti P, Tombesi P, Nielsen I, Trevisani L, et al. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions. J Clin Oncol. 2004;22:1228–33.CrossRefPubMed
54.
Ikuta K, Yano S, Trung VT, Hanibuchi M, Wang W, Yamada T, et al. E7080, a multityrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res. 2009;15:7229–37.CrossRefPubMed
55.
Jahan T, Gu L, Kratzke R, Dudek A, Otterson GA, Wang X, et al. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012;76:393–6.CrossRefPubMed
56.
Kindler HL, Vogelzang NJ, Chien K, Stadler WM, Karczmar G, Heimann R, et al. SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study. Proc Am Soc Clin Oncol. 2001;20:S1359.
57.
Janne PA, Wang XF, Krug LM, Hodgson L, Vokes EE, Kindler HL. Sorafenib in malignant pleural mesothelioma (MM): a phase II trial of the Cancer and Leukemia Group B (CALGB 30307). J Clin Oncol. 2007;25:S7707.CrossRef
58.
Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, Van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer. 2005;48:291–6.CrossRefPubMed
59.
Baas P, Buikhuisen W, Dalesio O, Vincent A, Pavlakis N, Van Klaveren R, et al. A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy. J Clin Oncol. 2011;29:S7006.
60.
Yanagawa H, Haku T, Hiramatsu K, Nokihara H, Takeuchi E, Yano S, et al. Intrapleural instillation of interferon gamma in patients with malignant pleurisy due to lung cancer. Cancer Immunol Immunother. 1997;45:93–9.CrossRefPubMed
61.
Boutin C, Viallat JR, Van Zandwijk N, Douillard JT, Paillard JC, Guerin JC, et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer. 1991;67:2033–7.CrossRefPubMed
62.
Boutin C, Nussbaum E, Monnet I, Bignon J, Vanderschueren R, Guerin JC, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer. 1994;74:2460–7.CrossRefPubMed
63.
Psallidas I, Karabela SP, Moschos C, Sherrill TP, Kollintza A, Maqkouta S, et al. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study. Mol Cancer. 2010;10(9):56.CrossRef
64.
Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med. 2012;186:487–92.CrossRefPubMed
65.
Ma X, Yao Y, Yuan D, Liu H, Wang S, Zhou C, et al. Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One. 2012;7:e53449.CrossRefPubMedPubMedCentral
66.
Fang SC, Zhang HT, Hu HD, Wang CY, Zhang YM. Effect of Endostar combined with angiopoietin-2 inhibitor on malignant pleural effusion in mice. Med Oncol. 2015;32:410.CrossRefPubMed
67.
Chen X, Liu Y, Yin Y, Jin S, Ping G, Røe OD, et al. Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma. J Chemother. 2012;24:231–6.CrossRefPubMed
Metadata
Title
Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases
Authors
D. Marquez-Medina
S. Popat
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 8/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1464-y

Other articles of this Issue 8/2016

Clinical and Translational Oncology 8/2016 Go to the issue

Research Article

ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker

Research Article

Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer

Research Article

Prognostic value of ZFP36 and SOCS3 expressions in human prostate cancer

Research Article

Aldehyde dehydrogenase isoform 1 (ALDH1) expression as a predictor of radiosensitivity in laryngeal cancer

Brief Research Article

Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data

Correspondence

Late recurrence (more than 10 years) in early (tumors equal to or smaller than 2 cm) breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits